newsfilter
← Latest News
ACCESS Newswire·

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable Disease Rate,